Faculty

Neil Kay

MD
Consultant
Mayo Clinic

Dr. Neil Kay is a Professor of Medicine, a Staff Consultant and a Career Scientist in the Division of Hematology, Department of Medicine at the Mayo Clinic. His medical subspecialty experience is in the field of Hematology and he has primarily focused on the study of B CLL. This work has led to national and international recognition of the Mayo Clinic CLL research program. He is also a member of the Eastern Cooperative Oncology Group where he is a core leukemia committee member and is a member of the National Cancer Institute leukemia steering committee. He is known for his clinical and biologic research in B cell hematologic malignancies where he focuses on the genetic features of CLL B cells, immunologic status of the CLL patient, interactions of CLL B cells with its microenvironment, clinical and biologic aspects of monoclonal B cell lymphocytosis and the development and conduct of unique clinical trials for early stage and upfront progressive CLL.

2027 Sessions

Continuous Therapy in CLL: Weighing the Newest Evidence

Speaker

Saturday, February 06 12:40–1:00 PM
Room King Ballroom 3
Faculty

Neil Kay

MD
Consultant
Mayo Clinic

Dr. Neil Kay is a Professor of Medicine, a Staff Consultant and a Career Scientist in the Division of Hematology, Department of Medicine at the Mayo Clinic. His medical subspecialty experience is in the field of Hematology and he has primarily focused on the study of B CLL. This work has led to national and international recognition of the Mayo Clinic CLL research program. He is also a member of the Eastern Cooperative Oncology Group where he is a core leukemia committee member and is a member of the National Cancer Institute leukemia steering committee. He is known for his clinical and biologic research in B cell hematologic malignancies where he focuses on the genetic features of CLL B cells, immunologic status of the CLL patient, interactions of CLL B cells with its microenvironment, clinical and biologic aspects of monoclonal B cell lymphocytosis and the development and conduct of unique clinical trials for early stage and upfront progressive CLL.

Q&A Panel

Moderator

Panelist

Saturday, February 06 1:20–1:30 PM
Room King Ballroom 3
Miami Regional Co-Chair

Jacqueline Barrientos

MD, MS
Chief Hematology Malignancies
Mount Sinai Medical Center

Jacqueline C. Barrientos, MD, MS, is an internationally recognized hematologist specializing in lymphoid malignancies, with a strong focus on chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and novel targeted therapies. She currently serves as faculty at Mount Sinai Braman Comprehensive Cancer Center in Miami Beach, where she leads clinical and translational research programs aimed at improving therapeutic strategies and long-term outcomes for patients with hematologic cancers. Dr. Barrientos has authored and co-authored a broad portfolio of peer-reviewed publications, book chapters, and invited reviews, and she is a frequent speaker at national and international conferences.
Dr. Barrientos completed her internship and residency in medicine at Yale-New Haven Hospital, and her fellowship in Hematology/Oncology at Weill Cornell in New York City. During fellowship, she completed a Masters degree in Clinical Investigation at Weill Cornell Graduate School of Medical Sciences. She is board certified in hematology and oncology and an Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She is the recipient of several awards including the American Society of Hematology Harold Amos Medical Faculty Development Program Award.
Throughout her research trajectory, Dr. Barrientos has served as principal investigator on numerous landmark clinical trials that contributed to the development and approval of multiple BTK inhibitors and other targeted agents in CLL. Her academic contributions also include mentorship of fellows and junior faculty, leadership in protocol development, and active involvement in initiatives promoting diversity and equity in clinical research.

Faculty

Neil Kay

MD
Consultant
Mayo Clinic

Dr. Neil Kay is a Professor of Medicine, a Staff Consultant and a Career Scientist in the Division of Hematology, Department of Medicine at the Mayo Clinic. His medical subspecialty experience is in the field of Hematology and he has primarily focused on the study of B CLL. This work has led to national and international recognition of the Mayo Clinic CLL research program. He is also a member of the Eastern Cooperative Oncology Group where he is a core leukemia committee member and is a member of the National Cancer Institute leukemia steering committee. He is known for his clinical and biologic research in B cell hematologic malignancies where he focuses on the genetic features of CLL B cells, immunologic status of the CLL patient, interactions of CLL B cells with its microenvironment, clinical and biologic aspects of monoclonal B cell lymphocytosis and the development and conduct of unique clinical trials for early stage and upfront progressive CLL.

Clinical Crossroads: A Case Discussion Panel in CLL

Moderator

Panelist

Saturday, February 06 4:00–4:50 PM
Room King Ballroom 3
Miami Regional Co-Chair

Jacqueline Barrientos

MD, MS
Chief Hematology Malignancies
Mount Sinai Medical Center

Jacqueline C. Barrientos, MD, MS, is an internationally recognized hematologist specializing in lymphoid malignancies, with a strong focus on chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and novel targeted therapies. She currently serves as faculty at Mount Sinai Braman Comprehensive Cancer Center in Miami Beach, where she leads clinical and translational research programs aimed at improving therapeutic strategies and long-term outcomes for patients with hematologic cancers. Dr. Barrientos has authored and co-authored a broad portfolio of peer-reviewed publications, book chapters, and invited reviews, and she is a frequent speaker at national and international conferences.
Dr. Barrientos completed her internship and residency in medicine at Yale-New Haven Hospital, and her fellowship in Hematology/Oncology at Weill Cornell in New York City. During fellowship, she completed a Masters degree in Clinical Investigation at Weill Cornell Graduate School of Medical Sciences. She is board certified in hematology and oncology and an Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She is the recipient of several awards including the American Society of Hematology Harold Amos Medical Faculty Development Program Award.
Throughout her research trajectory, Dr. Barrientos has served as principal investigator on numerous landmark clinical trials that contributed to the development and approval of multiple BTK inhibitors and other targeted agents in CLL. Her academic contributions also include mentorship of fellows and junior faculty, leadership in protocol development, and active involvement in initiatives promoting diversity and equity in clinical research.

LL&M Scientific Co-Chair

Richard Furman

MD
Morton Coleman, MD Distinguished Professor of Medicine
NewYork Presbyterian Hospital, Weill Cornell Medicine

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

Faculty

Neil Kay

MD
Consultant
Mayo Clinic

Dr. Neil Kay is a Professor of Medicine, a Staff Consultant and a Career Scientist in the Division of Hematology, Department of Medicine at the Mayo Clinic. His medical subspecialty experience is in the field of Hematology and he has primarily focused on the study of B CLL. This work has led to national and international recognition of the Mayo Clinic CLL research program. He is also a member of the Eastern Cooperative Oncology Group where he is a core leukemia committee member and is a member of the National Cancer Institute leukemia steering committee. He is known for his clinical and biologic research in B cell hematologic malignancies where he focuses on the genetic features of CLL B cells, immunologic status of the CLL patient, interactions of CLL B cells with its microenvironment, clinical and biologic aspects of monoclonal B cell lymphocytosis and the development and conduct of unique clinical trials for early stage and upfront progressive CLL.

Faculty

Erin Mulvey

MD
Assistant Professor
Weill Cornell Medicine

Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She competed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College. Dr. Mulvey has also completed a Master's Degree in Clinical Investigation and Translational Research at the Weill Cornell School of Graduate Sciences.

Dr. Mulvey is a member of the Weill Cornell Lymphoma Program where she specializes in treating patients with lymphoma and chronic lymphocytic leukemia (CLL) and is an active investigator in several clinical trials. Her research is centered on B cell lymphomas and CLL. Dr. Mulvey is focused on the study and manipulation of the interaction between the body’s own immune system and cancerous cells. She also has a special interest in health realted quality of life and the use of patient reported outcomes in clinical trials, and has received honors from the Lymphoma Research Foundation (LRF) and the NIH.

Faculty

Javier Pinilla Ibarz

MD, PhD
Senior Member and Head of Lymphoma Section
Moffitt Cancer Center

Javier Pinilla-Ibarz, MD, PhD, is physician scientist Senior Member, Head of Lymphoma Section and Director of Immunotherapy in the Malignant Hematology Department at H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida.

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006, and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. Dr. Pinilla-Ibarz has participated in multiple clinical trials involving several kinase inhibitors, many of them now FDA approved.
He has been involved in developing new immunotherapeutic approaches in malignant hematology with special emphasis of restoring the impaired immune response of patients with chronic leukemias. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. He has been involved in the development of a Wilms tumor 1 vaccine for leukemias and other solid tumor now in phase III trial across the world. His laboratory is interested in epigenetic immunoregulation in lymphoid malignancies such as B and T cell lymphomas through the use of epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other research focuses are on the interaction of kinase inhibitors with the immune system and how to use these drugs to improve current immune therapeutics approaches.

Back to top